MetaCap

Akebia Therapeutics (AKBA) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 4.7% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -96.2% for OKUR. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $107.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-75.13%OKUR+4.65%
+113%+15%-84%
Nov 21, 20251 yearNov 20, 2026
AKBA-86.13%OKUR-96.62%
+50%-27%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus OKUR key metrics
MetricAKBAOKUR
Share price$0.3855$2.70
Market cap$107.04M$111.21M
1-day change-8.71%-2.17%
YTD return-76.06%-6.90%
1-year return-75.13%+4.65%
5-year return-85.56%-96.16%
EPS (TTM)$-0.17$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M—
Revenue growth (YoY)+47.46%—
Net income (latest FY)$-5.34M$-59.52M
Gross margin83.29%—
Operating margin9.95%—
Net margin-2.26%—
52-week high$1.73$5.38
52-week low$0.361$2.01
Distance from 52-week high-77.72%-49.81%
Analyst consensusstrong_buynone
Avg. price target upside+678.21%+464.81%
Average volume8.05M335.78K
Shares outstanding277.66M40.50M
Employees19445
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKUR has outperformed AKBA by 79.8 percentage points over the past year.

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

AKBA vs OKUR FAQ

Which is bigger, Akebia Therapeutics or OnKure Therapeutics?

OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $107.04M for Akebia Therapeutics (AKBA).

Which stock has performed better over the past year, AKBA or OKUR?

OKUR returned +4.65% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons